Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Wait To Act On Plan B Petition Despite Contempt Complaint

This article was originally published in The Tan Sheet

Executive Summary

FDA does not plan to look at allowing wider access to nonprescription emergency contraceptive Plan B until Teva Pharmaceuticals files an application, despite a complaint accusing the agency of ignoring a court order to reconsider age restrictions on the product.
Advertisement

Related Content

Updated Plan B Lawsuit Could Expand EC Switch Targets
Updated Plan B Lawsuit Could Expand Emergency Contraceptive Switch Targets
Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle
HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
Study Suggests Emergency Contraception Potential For Regular Use
Study Suggests Emergency Contraception Potential For Regular Use
Teva's Plan B One-Step OTC Application Puts FDA On The Spot
Sebelius Plans To Leave Plan B Decision To Science
Plan B Ruling: Little Commercial Impact, Big Policy Implications
Advertisement
UsernamePublicRestriction

Register

PS104689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel